Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. Knight Therapeutics Inc.
  6. News
  7. Press Releases
    GUD   CA4990531069

KNIGHT THERAPEUTICS INC.

(GUD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Communiqués de presse de la société KNIGHT THERAPEUTICS INC.
12/02Knight to Present at Stifel GMP's The Future of Healthcare Conference
GL
12/02Knight to Present at Stifel GMP's The Future of Healthcare Conference
GL
11/11Knight Therapeutics Reports Third Quarter 2021
AQ
11/05Notice of Knight Therapeutics Third Quarter 2021 Results Conference Call
AQ
11/04Notice of Knight Therapeutics' Third Quarter 2021 Results Conference Call
GL
11/04Notice of Knight Therapeutics' Third Quarter 2021 Results Conference Call
GL
09/23INCYTE : Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with ..
AQ
08/16KNIGHT THERAPEUTICS : Reports Second Quarter 2021
AQ
08/06Notice of Knight Therapeutics' Second Quarter 2021 Results Conference Call
GL
07/12KNIGHT THERAPEUTICS : Announces Normal Course Issuer Bid
AQ
07/06KNIGHT THERAPEUTICS : Announces Health Canada Approval for NERLYNX® (Neratinib) to Treat H..
AQ
05/27KNIGHT THERAPEUTICS : Announces Closing of Previously Announced Acquisition and Exclusive ..
AQ
05/13KNIGHT THERAPEUTICS : IIROC Trade Resumption - GUD
AQ
05/13KNIGHT THERAPEUTICS : IIROC Trading Halt - GUD
AQ
05/12KNIGHT THERAPEUTICS : to Present at the 2021 RBC Capital Markets Global Healthcare Confere..
AQ
05/07Notice of Knight Therapeutics' First Quarter 2021 Results Conference Call
GL
05/03KNIGHT THERAPEUTICS : Maverix Private Equity Announces Team Additions
AQ
04/26KNIGHT THERAPEUTICS : to Acquire Regional Rights to Exelon
AQ
03/25Knight Therapeutics Reports Fourth Quarter and Year End 2020 Results
GL
2020KNIGHT THERAPEUTICS : S&P Dow Jones Indices Announces Changes to the S&P/TSX Composite Ind..
AQ
2020KNIGHT THERAPEUTICS : Reports Third Quarter 2020 Results
AQ
2020Knight Therapeutics Reports Third Quarter 2020 Results
GL
2020KNIGHT THERAPEUTICS : Notice of Knight Therapeutics' Third Quarter 2020 Results Conference..
AQ
2020Notice of Knight Therapeutics' Third Quarter 2020 Results Conference Call
GL
2020KNIGHT THERAPEUTICS : Signs New Exclusive AmBisome® Agreement with Gilead in Brazil
AQ
2020Knight Signs New Exclusive AmBisome® Agreement with Gilead in Brazil
GL
2020KNIGHT THERAPEUTICS : and Therapeutics MD Announce Health Canada Approval of BIJUVA
AQ
2020KNIGHT THERAPEUTICS : and TherapeuticsMD Announce Health Canada Approval of BIJUVA®
AQ
2020Knight and TherapeuticsMD Announce Health Canada Approval of BIJUVA®
GL
2020KNIGHT THERAPEUTICS : Announces Filling of Supplement to a New Drug Submission for NERLYNX..
AQ
2020Knight Therapeutics Announces Filling of Supplement to a New Drug Submission for NERLYN..
GL
2020KNIGHT THERAPEUTICS : and TherapeuticsMD Announce Health Canada Approval of IMVEXXY
AQ
2020KNIGHT THERAPEUTICS : and TherapeuticsMD Announce Health Canada Approval of IMVEXXY®
AQ
2020Knight and TherapeuticsMD Announce Health Canada Approval of IMVEXXY®
GL
2020KNIGHT THERAPEUTICS : Completes the Tender Offer for Grupo Biotoscana And Achieves Over 95..
AQ
2020Knight Therapeutics Completes the Tender Offer for Grupo Biotoscana And Achieves Over 9..
GL
2020KNIGHT THERAPEUTICS : Reports Second Quarter 2020 Results
AQ
2020Knight Therapeutics Reports Second Quarter 2020 Results
GL
2020KNIGHT THERAPEUTICS : Notice of Knight Therapeutics' Second Quarter 2020 Results Conferenc..
AQ
2020KNIGHT THERAPEUTICS : Announces the Launch of the Tender Offer for remaining 48.8% of Grup..
AQ
2020KNIGHT THERAPEUTICS : Announces Normal Course Issuer Bid
AQ
2020KNIGHT THERAPEUTICS : Announces CVM Approval of the Tender Offer for remaining 48.8% of Gr..
AQ
2020KNIGHT THERAPEUTICS : Reports First Quarter 2020 Results
AQ
2020KNIGHT THERAPEUTICS INC. : announces voting results from the Annual Meeting
AQ
2020KNIGHT THERAPEUTICS : Notice of Knight Therapeutics' First Quarter 2020 Results Conference..
AQ
2020KNIGHT THERAPEUTICS INC. :  Announces Further Update on Extension of First Quarter 2020 Fi..
AQ
2020KNIGHT THERAPEUTICS : to Present at the Jefferies 2020 Virtual Global Healthcare Conferenc..
AQ
2020KNIGHT THERAPEUTICS INC. :  Announces Extension of First Quarter 2020 Filings due to COVID..
AQ
2020TELO GENOMICS : Repurchases Canadian Licensing and Commercialization Rights
AQ
2020KNIGHT THERAPEUTICS : Announces the Re-Launch of Trelstar® in Canada
AQ
2020KNIGHT THERAPEUTICS : Announces Approval of IBSRELA™ in Canada
AQ
2020KNIGHT THERAPEUTICS INC. :  Announces Triumvira Loan Repayment
AQ
2020KNIGHT THERAPEUTICS INC. :  Announces Completion of its Normal Course Issuer Bid
AQ
2020KNIGHT THERAPEUTICS : Files Annual Information Form
AQ
2020KNIGHT THERAPEUTICS : Reports Fourth Quarter and Year End 2019 Results
AQ
2020KNIGHT THERAPEUTICS : Notice of Knight Therapeutics' Fourth Quarter 2019 Results Conferenc..
AQ
2020KNIGHT THERAPEUTICS : Announces Closing of Separation Agreement
AQ
2020KNIGHT THERAPEUTICS : Quebec, New Brunswick, Newfoundland, Nova Scotia and Manitoba join A..
AQ
2020KNIGHT THERAPEUTICS : Partners with Debiopharm for the Commercialization of Trelstar® in C..
AQ
2020KNIGHT THERAPEUTICS : to Present at the J.P. Morgan Healthcare Conference in San Francisco
AQ
2019KNIGHT THERAPEUTICS : Announces Submission to B3 S.A. For Unified Tender Offer
AQ
2019KNIGHT THERAPEUTICS : Announces Closing of Previously Announced Acquisition of Grupo Bioto..
AQ
2019KNIGHT THERAPEUTICS : and Therapeutics MD Announce Filing of New Drug Submission for BIJUV..
AQ
2019KNIGHT THERAPEUTICS : Profound Medical Announces Health Canada Approval of TULSA-PRO
AQ
2019KNIGHT THERAPEUTICS : and TherapeuticsMD Announce Filing of New Drug Submission for Bijuva..
AQ
2019KNIGHT THERAPEUTICS : GUD Medison Resolved
AQ
2019KNIGHT THERAPEUTICS : Medison Urges Knight Therapeutics and Jonathan Goodman to Aggressive..
BU
2019KNIGHT THERAPEUTICS : Israeli Courts Rule Against Knight Therapeutics' and Jonathan Goodma..
BU
2019KNIGHT THERAPEUTICS : Medison Biotech Considers Requisition of Special Meeting of Sharehol..
BU
2019MEDISON BIOTECH : Jonathan Goodman Takes Advantage of His Own Failure to Create Value, Enr..
BU
2019KNIGHT THERAPEUTICS : Medison Establishes Canada's Only Innovative Pharma Commercial Compa..
BU
2019KNIGHT THERAPEUTICS : Medison Issues Open Letter to Knight Therapeutics Shareholders Urgin..
BU
2019KNIGHT THERAPEUTICS : Medison Creates Significant Change at Knight Therapeutics
BU
2019KNIGHT THERAPEUTICS : Medison Campaign Successfully Creates Unanimous Consent for Change a..
BU
2019KNIGHT THERAPEUTICS : Second Leading Independent Proxy Advisory Firm Supports Medison and ..
BU
1  2  3Next
Upcoming event on KNIGHT THERAPEUTICS INC.
12/08/21